- Super immunodeficient NOG mouse expressing human IL-2 cytokine.
- Predominant differentiation of human NK cells following human HSC engraftment, with>10-fold higher CD56+ NK cell numbers compared to the base NOG mouse.
- Human NK cells developed in hIL-2 NOG mice express various NK receptors and produce both granzyme A and perforin upon stimulation.
- May be an improved model for differentiation/engraftment of IL-2 dependent cells including certain blood cancers.
- May be useful for efficacy studies involving antibody therapeutics with antibody dependent cell cytotoxcity mechanism of action.
- Applications in research involving cancer, infectious disease, immunology, regenerative medicine and human immune system engraftment.
- As of July 2022, internal and external testing and data indicates that hIL-2 NOG mice produce human IL-2 in the range of 0.5-2.0 ng/mL (as measured by ELISA DBS). Based on user feedback, this level appears sufficient to support engraftment of primary human T cells.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
What our customers say:
“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”Experimental Pharmacology & Oncology (EPO) GmbH
Origin:
The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The hIL-2 NOG mouse was developed by microinjecting a transgene consisting of a DNA fragment containing human IL-2 cDNA under the control of the CMV promoter into zygotes of NOD/ShiJic-Il2rg mice. Founders were backcrossed to NOG mice to establish the hIL-2 NOG line. Taconic received stock in 2014, and the line was derived through embryo transfer. Availability:
Available now*
*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3-weeks of age. Color:
Albino Species:
Mouse Initial Publication:
- Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γ
mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.
- Fukuchi Y, Miyakawa Y, Kobayashi K, Kuramochi T, Shimamura K, Tamaoki N, Nomura T, Ueyama Y, Ito M. (1998) Cytokine dependent growth of human TF-1 leukemic cell line in human GM-CSF and IL-3 producing transgenic SCID mice. Leuk Res 22(9):837-43.
- Katano I, Takahashi T, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M. (2015) Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse. J Immunol. 194(7):3513-25.
